Close Menu

NEW YORK – Veracyte reported after the close of the market on Tuesday that its fourth quarter revenues rose 15 percent year over year.

For the three months ended Dec. 31, 2019 the South San Francisco, California-based genomics diagnostics firm posted $29.7 million in revenues, up  from $25.8 million in Q4 2018 and above analysts' average estimate of $29.5 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.